Kyongbo Pharma says court stays product approval cancellations pending appeal ruling

PUBT · 2d ago
Kyongbo Pharma says court stays product approval cancellations pending appeal ruling
  • Kyongbo Pharmaceutical disclosed a court-ordered stay on the effectiveness of product license cancellations tied to its business suspension case.
  • The stay runs until 30 days after an appellate ruling in the main lawsuit seeking to overturn the license-cancellation measure.
  • The suspension-related affected sales were KRW 13.48 billion, equal to 5.65% of 2024 revenue of KRW 238.56 billion.
  • The license cancellations had been set to take effect from June 24, 2025.
  • The company plans to update disclosures depending on the appellate court’s decision on the merits.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyongbo Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930000336), on September 30, 2026, and is solely responsible for the information contained therein.